Pharsight

Kyleena patents expiration

KYLEENA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7252839 BAYER HLTHCARE Delivery system and a manufacturing process of a delivery system
Nov, 2023

(7 months ago)

US11628088 BAYER HLTHCARE Ultrasonically detectable intrauterine system and a method for enhancing ultrasound detection
Feb, 2027

(2 years from now)

US11850182 BAYER HLTHCARE Inserter
Sep, 2029

(5 years from now)

US10561524 BAYER HLTHCARE Inserter
Sep, 2029

(5 years from now)

US9615965 BAYER HLTHCARE Inserter
Sep, 2029

(5 years from now)

US10987244 BAYER HLTHCARE Inserter
Apr, 2031

(6 years from now)

US9668912 BAYER HLTHCARE Inserter
Apr, 2031

(6 years from now)

Kyleena is owned by Bayer Hlthcare.

Kyleena contains Levonorgestrel.

Kyleena has a total of 7 drug patents out of which 1 drug patent has expired.

Expired drug patents of Kyleena are:

  • US7252839

Kyleena was authorised for market use on 16 September, 2016.

Kyleena is available in intrauterine device;intrauterine dosage forms.

Kyleena can be used as a method of positioning an intrauterine system by holding an inserter handle with one hand, advancing the inserter through the cervix and into the uterus, and retracting a slider on the handle to release the intrauterine system, a method of preventing pregnancy by providing an intrauterine system (ius), holding an inserter handle with one hand, inserting the ius into the uterus, and moving a slider in the handle to release the ius within the uterus, a method of positioning an intrauterine system (ius) by determining a depth of the uterus, holding an inserter handle with one hand, inserting the ius into the uterus, and retracting a slider on the handle to release the ius into the uterus.

The generics of Kyleena are possible to be released after 01 April, 2031.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 16, 2019

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 16 September, 2016

Treatment: A method of preventing pregnancy by providing an intrauterine system (ius), holding an inserter handle with one hand, inserting the ius into the uterus, and moving a slider in the handle to release th...

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage

KYLEENA family patents

Family Patents